Sequana announced the publication of a case report of a patient in the POSEIDON study that underwent a successful robotic hernia repair following control of their ascites with the alfapump. Looking ahead, the US commercial launch remains on track for this quarter. Should the company demonstrate initial commercial traction during the soft launch phase, this could trigger additional investor interest to fund the company into the broader launch, which is expected in 2Q26. We reiterate our € 5 TP an...
AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...
Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2025. Key Highlights Strong revenue performance with 10.9% reported revenue growth (14.4% at CER1) and 11.3% organic growth at CER 12.3% R...
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van REBITDA in H1 2025 Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 31 juli 2025 – 07.00 uur CET Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van REBITDA in H1 2025 Fagron, de toonaangevende wereldwijde speler op het gebied van farmaceutische compounding, publiceert vandaag haar eerste halfjaarresultaten voor de periode eindigend op 30 juni 2025. Belangrijkste hoogtepunten Sterke omzetresultaten met een gerapporteerde omzetgroei van 10,9% (1...
We update the performance of our ING Benelux Favourites list as well as all valuation and ranking tables for our coverage universe. Performance on the front page is dated from the 27 January 2025, while historical performance is included on the second page. The methodology for our favourites selection is based on a bottom-up approach with a focus on absolute performance with clear near-term triggers. It is a rolling list, ie, stocks can enter/exit whenever we think opportune. The ING Benelux Fav...
Openbaarmaking van kennisgeving ontvangen van Alychlo Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 18 juli 2025 – 18 CET Openbaarmaking van kennisgeving ontvangen van Alychlo Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van Alychlo NV. Kennisgeving van Alychlo NV Op 14 juli 2025 ontving Fagron een melding dat het belang van Alychlo NV de meldingsdrempel van 3% had overschreden als gevolg van de verkoop van stemrechtverlenende effecten of s...
Disclosure of notification received from Alychlo Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET Disclosure of notification received from Alychlo Fagron received a notification based on the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Alychlo NV. Notification by Alychlo NV On 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the disposal of voting securities or voting rights on 25 July 2024....
We’ve raised our medium term estimates for Fagron, expecting mid-term sales growth of 8.3% versus guidance (high single digit), likely topped by 2% via M&A and further supported by rising (AA-OB at 20.8% for 2027) margins (21% by 2027). At ~13.3x (AA-OB) 2026 P/E, Fagron is valued attractively, leading us to raise our target price to €27 per share.
We update our model and target price to reflect recent adverse FX trends, with our organic growth assumptions unchanged. We reiterate our BUY on Fagron, an ING Benelux Favourite, as its strengthening track record, high visibility on organic growth and attractive valuation at c.9x/8x 2026F/2027F EV/EBITDA, lay the grounds for a re-rating as the company further executes on its growth agenda.
Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...
We raise our target price to €26 per share from €22.5 and reiterate our BUY recommendation, as we find Fagron's recent step-up in growth targets is not yet priced in. Given high visibility on organic growth, attractive value and a strengthening track record, Fagron remains on the ING Benelux Favourites list.
In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...
Fagron increases share capital through exercise subscription rights Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 85,000 new shares have been issued on 6 June 2025. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 504,303,905.59. The total number of shares with voting rights after the issue amounts to 73,313,904 which is also ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.